Iron
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Iron
- Iron: From Iron Deficiency to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anaemia
Iron: From Iron Deficiency to Vitamin B12- and Folate-Independent Constitutional Megaloblastic Anaemia
One-Sentence Summary
Iron is a mineral supplement used to treat and prevent iron deficiency. The registration data supplied does not state approved indications, so this description rests on general knowledge of the product class. The TxGNN model predicts it may be effective for vitamin B12- and folate-independent constitutional megaloblastic anaemia, but no clinical trials and no publications support this specific prediction. The mechanism also does not fit well, so this is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Iron deficiency (general knowledge; approved indication text was not provided in the SAHPRA records supplied) |
| Predicted New Indication | Vitamin B12- and folate-independent constitutional megaloblastic anaemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 11 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, iron is an essential mineral needed for haemoglobin synthesis and red blood cell production. Its efficacy in correcting iron deficiency is well established.
The predicted condition is a megaloblastic anaemia, which reflects impaired DNA synthesis in red cell precursors rather than a lack of iron. A direct iron mechanism is therefore not evident. The very high score most likely reflects proximity to other anaemia-related nodes in the knowledge graph, not a true therapeutic link. On mechanism alone, this prediction is weak.
Clinical Trial Evidence
Currently no related clinical trials registered (ClinicalTrials.gov, ICTRP, SANCTR or PACTR) for this predicted indication.
Literature Evidence
Currently no related literature available for this predicted indication.
Note on other predictions: The second-ranked prediction, Plummer-Vinson syndrome (score 99.89%), has far stronger support and is the most actionable finding in this pack. The syndrome is defined by iron deficiency anaemia, dysphagia and oesophageal webs. The evidence is reviews and case reports only, with no controlled trials. Iron repletion here is existing standard care rather than a novel repurposing signal. Key publications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29089792 | 2017 | Review | J Blood Med | Current insights on the triad of iron deficiency anaemia, dysphagia and oesophageal web |
| 16978405 | 2006 | Review | Orphanet J Rare Dis | Rare syndrome, mostly middle-aged women; overview of clinical features |
| 12823219 | 2003 | Case report | Dis Esophagus | Two women treated with iron supplementation; symptoms resolved |
| 7575056 | 1995 | Case report and review | Arch Intern Med | Iron repletion often improves dysphagia; some need dilation; surveillance endoscopy advised because of postcricoid carcinoma risk |
| 31417270 | 2019 | Review | J Multidiscip Healthc | Multidisciplinary management; long-term surveillance for malignancy |
| 41756818 | 2026 | Case report | Case Rep Hematol | Diagnosis and management in a Ghanaian woman |
South Africa Market Information
Showing 5 of 11 registrations.
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 32/8.3/0166 | Venofer ampoule 5ml | Injection |
| Reg. No. 46/8.3/0166 | Monofer vial 1ml | Injection |
| Reg. No. 46/8.3/0849 | Rautevene solution for injection ampoule | Injection |
| H842 (Act 101 of 1965) | Ferrimed | Syrup |
| L/24/329 | Dextrose 20% in water 500ml pcd201850 | Infusion |
Approved indication text was not provided for these registrations. The dextrose infusion entry appears to be a parenteral nutrition product, and its link to iron should be verified against its Professional Information (PI). Essential Medicines List (EML) status was not included in the data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Literature retrieved for this pack flags one safety issue: certain intravenous iron formulations can cause hypophosphatemia through increased FGF23 secretion (PMID 34534708, a 2022 review in Bone). This is relevant to the IV products registered in South Africa.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction rests only on a model score, with no trials or publications. It is also mechanistically implausible, because megaloblastic anaemia is a disorder of DNA synthesis rather than iron deficiency. The only well-supported iron link in this pack is Plummer-Vinson syndrome, which is existing standard care and not a new repurposing opportunity.
To proceed, the following is needed:
- Retrieval of SAHPRA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Confirmation of approved indications for the 11 SAHPRA registrations
- A clinical rationale, if any, for iron in constitutional megaloblastic anaemia, otherwise drop this prediction
- If pursuing the Plummer-Vinson syndrome entry, a formal review of the case-level evidence, framed as confirming standard care
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.